The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Bortezomib is a proteasome inhibitor with demonstrated efficacy in non-small cell lung cancer (NSCLC).
• However, patient response to bortezomib is heterogeneous, necessitating an understanding of resistance mechanisms.
• Differential sensitivity among NSCLC cell lines suggests underlying biological variability.

Purpose of the Study:

• To investigate the differential sensitivity of NSCLC cell lines to bortezomib.
• To explore the roles of apoptotic and proteasomal phenotypes in bortezomib response.
• To elucidate mechanisms of bortezomib resistance in NSCLC.

Main Methods:

• Assessed bortezomib sensitivity using IC50 values across various NSCLC cell lines.
• Evaluated apoptosis induction and proteasome inhibition following bortezomib treatment.
• Investigated the effect of Bcl-2 overexpression on bortezomib-induced apoptosis and proteasome inhibition.

Main Results:

• NSCLC cell lines exhibited a wide range of sensitivities to bortezomib (IC50: 5-83 nM).
• Apoptosis induction by bortezomib was dependent on both cellular apoptotic and proteasomal phenotypes.
• H460 cells showed higher susceptibility to apoptosis upon effective proteasome inhibition, while SW1573 cells responded to lower bortezomib doses, indicating distinct phenotypes.
• Bcl-2 overexpression reduced bortezomib-induced apoptosis in H460 cells without altering their proteasomal phenotype.

Conclusions:

• Successful proteasome inhibitor therapy in NSCLC requires overcoming both apoptosis and proteasome resistance.
• Individual NSCLC cell characteristics significantly influence response to bortezomib.
• Further research is needed to fully understand and target resistance mechanisms in NSCLC.